Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gingko extract for curing neurotoxicity induced by therapeutic agent

A technology of ginkgo extract and neurotoxicity, which is applied in the field of neurotoxicity treatment and related pharmaceutical compositions, and can solve the problems of increased treatment time and cost

Inactive Publication Date: 2007-08-08
GEORGETOWN UNIV
View PDF19 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are data showing that this approach is effective, it seems to benefit only 10-20% of patients and results in a substantial increase in treatment time and cost for patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] We assayed commercially available Ginkgo biloba extract containing standardized EGb 761 (Ginkgoba TM ) OTC formulation in patients receiving oxaliplatin. All patients received oxaliplatin and developed neurotoxicity before starting Ginkgo extract. Our recommended Ginkgoba based on our data and written reports TM The dose is 120 mg twice a day and taken continuously (daily). Acute neurotoxicity was determined according to the patient's medical history before receiving Ginkgo extract (the first few courses of chemotherapy) and compared with the situation after using Ginkgo extract (subsequent courses of chemotherapy). We treated 8 patients who developed significant neurotoxicity induced by the treatment, but the anticancer agent oxaliplatin used still had an anticancer effect in vivo. These patients received Ginkgoba 120 mg twice daily continuously while on oxaliplatin and for 1 to 2 months after discontinuing oxaliplatin. TM , taking for several months. Seven of eig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention features methods for treating neurotoxicity associated with therapeutic agents, e.g., chemotherapeutic agents, and compositions and kits for use therein. The methods employ an extract of Ginkgo biloba to mitigate the neurotoxic effects of the therapeutic agents.

Description

Background of the invention [0001] The present invention relates to the treatment of neurotoxicity and related pharmaceutical compositions. [0002] Many therapeutics used to treat diseases such as cancer cause undesirable neurological side effects, thus limiting their use. Often, there is no treatment for these side effects, and patients on treatment have to discontinue a drug or all medications for a period of time after reaching a therapeutic threshold. Such interruptions may adversely affect the patient's treatment, for example, requiring the use of a drug with fewer side effects but less therapeutic efficacy. [0003] In one example, oxaliplatin is an important therapeutic agent in the treatment of progressive colon cancer, a disease that affects 50,000 patients in the United States each year. The use of oxaliplatin could be expanded to include other patients with gastrointestinal and ovarian cancer. In summary, this drug is a well-tolerated drug but has significant ne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K49/00A01N65/00
Inventor J·L·马沙尔V·帕帕多普洛斯
Owner GEORGETOWN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com